2023 World Conference on Lung Cancer (Posters)-EP06.03. HRR Gene Mutations- A New Biomarker for Precision Genomics Based Testing in Metastatic Lung Cancer

EP06.03. HRR Gene Mutations- A New Biomarker for Precision Genomics Based Testing in Metastatic Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

A study was conducted to develop a new biomarker, HRR gene mutations, for precision genomics-based testing in metastatic lung cancer. The study analyzed 228 cancer patients who underwent genetic testing for the presence of HRR gene mutations. The HRR gene mutations were detected using next generation sequencing and the reported variants were annotated using ACMG and AMP guidelines. Out of the 228 patients analyzed, the overall prevalence of HRR gene mutations was 26.31%. In a subgroup of 30 patients with metastatic lung cancer, at least one HRR gene mutation was detected in 26.66% of patients. The study also compared the differences in tumor mutation burden (TMB), PD-L1 status, and MSI status between HRR gene mutated and HRR gene wild-type groups, but no statistically significant differences were found. The study found that 16.66% of the patients had precision genomics-based targetable mutations, while 83.33% had non-targetable mutations. In terms of first-line systemic therapy, 30% of patients received platinum-based chemotherapy only, 50% received chemotherapy and immunotherapy, 10% received immunotherapy only, and 10% received targeted therapy. The study concludes that the addition of HRR gene mutations as a biomarker in lung cancer testing promotes opportunities for further clinical trials to assess the efficacy of combining PARP inhibitors with immunotherapy in the future.

Asset Subtitle

Madhu Nagaraj

Meta Tag

Speaker Madhu Nagaraj

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

biomarker

HRR gene mutations

precision genomics

metastatic lung cancer

genetic testing

next generation sequencing

tumor mutation burden

PD-L1 status

targetable mutations

PARP inhibitors